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a b s t r a c t
The human ATP-binding cassette B5 (ABCB5) transporter, a member of the ABC transporter superfamily,
is linked to chemoresistance in tumour cells by drug effluxion. However, little is known about its struc-
ture and drug-binding sites. In this study, we generated an atomistic model of the full-length human
ABCB5 transporter with the highest quality using the X-ray crystal structure of mouse ABCB1 (Pgp1), a
close homologue of ABCB5 and a well-studied member of the ABC family. Molecular dynamics simula-
tions were used to validate the atomistic model of ABCB5 and characterise its structural properties in
model cell membranes. Molecular docking simulations of known ABCB5 substrates such as taxanes,
anthracyclines, camptothecin and etoposide were then used to identify at least three putative binding
sites for chemotherapeutic drugs transported by ABCB5. The location of these three binding sites is pre-
dicted to overlap with the corresponding binding sites in Pgp1. These findings will serve as the basis for
future in vitro studies to validate the nature of the identified substrate-binding sites in the full-length
ABCB5 transporter.
 2020 The Author(s). Published by Elsevier B.V. on behalf of Research Network of Computational and
Structural Biotechnology. This is an open access article under the CC BY-NC-ND license (http://creative-
commons.org/licenses/by-nc-nd/4.0/).
1. Introduction
Human ATP-binding cassette B5 (ABCB5) transporter is an inte-
gral membrane protein and a member of the ATP-binding cassette
(ABC) transporter superfamily. ABCB5 transporters are predomi-
nantly expressed in pigmented cells such as melanocytes and reti-
nal epithelial cells. However, the physiological relevance of these
transporters in these cells remains unknown. ABCB5 exists in four
isoforms, formed by alternative splicing: isoform 1 (ABCB5a;
ABCB5.f), isoform 2 (ABCB5b; ABCB5.a), isoform 3 (ABCB5.e) and
isoform 4 (ABCB5 full-length; ABCB5.ts) [9,27]. Of these four iso-
forms, the ABCB5b isoform (817 amino acids) and full-length
(1257 amino acids) have been identified to function as drug efflux
pumps by in vitro studies [29,44]. The ABCB5a and ABCB5.e iso-
forms are considered non-functional due to the absence of an
intact domain that facilitates drug binding [9]; the significance of
these two isoforms is unknown.
Expression of ABCB5b and its full length form have been
reported to occur in numerous cancer types such as colon, liver
and breast cancer, leukaemia, head and neck, oral squamous cell
and merkel cell carcinoma, [27,28,32,33,48]. In tumour cells, the
expression of ABCB5 is linked to multidrug resistance (MDR)
[10]. ABCB5 transporter extrudes anti-cancer drugs accumulated
within tumour cells, conferring resistance, in a similar fashion to
ATP-binding cassette B1 (ABCB1; P-glycoprotein 1; Pgp1) trans-
porter [10,28,44].
The drug efflux activity of ABCB5 was first reported by Frank
et al. showing that MCF-7 cells (breast carcinoma) expressing
ABCB5b isoform had an increased efflux of rhodamine 123 [29].
In a follow up study, decreased accumulation of doxorubicin and
5-fluorouracil was observed in ABCB5b-enriched melanoma
G3361 cells compared to the ABCB5b low population [28]. Later,
Kawanobe et al. demonstrated the efflux of several chemothera-
peutic drugs in HEK293 cells overexpressing the full-length ABCB5
isoform [44]. Furthermore, another study compared the efflux
action of the ABCB5b and full-length ABCB5 isoforms in yeast cells
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(S. cerevisiae) overexpressing the two isoforms. The study reported
that full-length ABCB5 was functional and conferred resistance for
rhodamine 123, daunorubicin and clorgyline; however, ABCB5b-
overexpressing cells did have resistance [46]. As chemoresistance
rendered by full-length ABCB5 is now established by multiple
studies, characterising its drug binding sites will shed more light
on the substrate specificity of the transporter.
A typical functional human ABC full transporter such as Pgp1
comprises of two transmembrane domains (TMDs), each com-
prised of six a-helices, and two cytosolic nucleotide-binding
domains (NBDs) interconnected by a linker region (Fig. 1). The
structural topology of the full-length ABCB5 isoform (1257 amino
acids in a single polypeptide chain) comprises two TMDs and
two NBDs interconnected by a linker region (Fig. 1), similar to
Pgp1 [59].
Pgp1 and ABCB5 are close homologues and, in fact, the two
transporters belong to the same subfamily ABCB. Pgp1 is the most
studied transporter that acts as a MDR mediator in cancer. Numer-
ous site-directed mutagenesis and structure-based studies have
described the molecular mechanisms involved in substrate translo-
cation, as well as the conformational changes that occur during this
process. While ABC transporters are known to transition between
open-inward and closed-outward conformations during the trans-
port cycle, their open-inward facing conformation is the resting
state conformation which allows molecules to interact with the
transporter [2,31]. Over the last decade, numerous structures of
open-inward and closed-outward facing Pgp1 transporters were
solved by X-ray diffraction crystallography and, more recently, by
cryoelectron microscopy [1,2,26,47,49,83]. These X-ray structures
have revealed that crystallographic conditions such as the presence
of different detergents, nucleotides or ligands can influence the
conformation of the transporter [4,67]. Extensive mutagenesis
studies of Pgp1, through cysteine, alanine or arginine replacement
approaches, led to the identification of residues in the TMD, NBD
and loops implicated in the binding and translocation of its sub-
strates [53–55,57]. Biochemical (mutagenesis) and pharmacologi-
cal studies, such as drug accumulation, ATPase and transport
assays, have revealed that multiple, distinct binding sites exist
within Pgp1 and are specific to the class of substrates being trans-
ported. Three pharmacological binding sites have been proposed
based on competitive binding of different substrates, namely the
R-site (rhodamine 123), the H-site (Hoechst 33342) and the vin-
blastine/prazosin binding site [56,57,78]. The R- and H-sites of
Pgp1 interact in a positively cooperative manner, thus impacting
substrate efflux [78]. In the presence of other substrates, the vin-
blastine site binds in a non-competitive manner, indicating that
it has an additional binding site [56]. In the last two decades,
numerous structural models of Pgp1 have been generated for
experimental and computational studies [7,63,71,72,73] to charac-
terise protein-drug interactions by molecular docking simulations
[19,63,64,73,90]. Molecular docking simulations indeed confirmed
the existence of R- and H- sites as substrate binding sites, while the
vinblastine site was predicted to be modulator binding site [22,19].
In this work, a high-quality, atomistic model of the human full-
length ABCB5 transporter was generated using the crystal struc-
ture of mouse Pgp1 in its open-inward facing conformation. To
assess the stability and conformations of this structure in a model
cell membrane environment, molecular dynamics (MD) simula-
tions were conducted. This was followed by molecular docking
simulations with known substrates of ABCB5 to identify their puta-
tive drug binding sites. The predicted binding interactions of rho-
damine 123 and paclitaxel were contrasted with site-directed
mutagenesis data for rhodamine 123 and crystallographic data
for paclitaxel in human Pgp1.
2. Materials and methods
2.1. Multiple sequence alignment
The FASTA sequence of mouse Pgp1 (UniProt ID: P21447-1),
human Pgp1 (UniProt ID: PO8183-1) and full-length human ABCB5
(UniProt ID: Q2M3G0-4) were downloaded from the UniProt data-
base (www.uniprot.org). Multiple sequence alignment was gener-
ated using Clustal Omega (ClustalO), with transition matrix
Gonnet, using the default setting with a gap opening penalty of
6, and a gap extension of 1. Multiple sequence alignment of full-
length human ABCB5 with the human Pgp1 and mouse Pgp1 FASTA
sequences revealed a high sequence identity (~54%) and similarity
(~74%) with both human and mouse Pgp1 sequences (Fig. S1 in the
Supplementary Information), which is excellent for homology
modelling [75]. As expected, a higher sequence identity was
observed in the residues corresponding to the NBD regions of these
three sequences, relative to the TMDs, as both ABCB5 and Pgp1
belong to the same ABCB subfamily.
2.2. Protein modelling
Initially, seventeen different structural models of human full-
length ABCB5 transporter were generated by homology modelling
using Phyre2 (Protein Homology/analogy Recognition Engine V2.0)
[45], SWISS MODEL [6,88] and MODELLER [23], as well as by
threading using I-TASSER [91]. The FASTA sequence of full-length
human ABCB5 (Q2M3G0-4) was submitted to Phyre2, and I-
TASSER servers, whilst sequence alignment of ABCB5 and the tem-
plate (PDB ID 4Q9H) was submitted to SWISS MODEL (alignment
mode) [6,88]. Template selection in Phyre2 is automated, and
structural models were generated using the structures of Pgp1
from Caenorhabditis elegans (PDB ID 4F4C, with a resolution of
3.4 Å) [42] and mouse Pgp1 (PDB ID 3G60, with a resolution of
4.4 Å) [2] as target proteins. Both the normal and intensive modes
in Phyre2 were used. The normal and intensive modes in Phyre2
work in a similar manner up to the point of sequence alignment.
In the case of normal mode, the HH search alignment algorithm
is used to generate backbone models followed by loop and side
chains modelling. In the case of intensive mode, models are gener-
ated for each selected template using Poing, a multi-template
modelling tool. Poing is used only in intensive mode to create com-
plete models of input protein sequences from separate templates.
If templates are not available then Poing uses ab initio modelling
for the missing regions. The intensive mode in Phyre2 has been
reported to perform a more refined model selection compared to
the normal mode based on sequence identity, confidence and cov-
erage [45]. Both modes were thus used for the generation of ABCB5
models.
Fig. 1. Predicted structural topology of full-length human ABCB5 isoform. The
topology of the full-length isoform is comprised of two TMDs and two cytosolic
NBDs interconnected by a linker region. Each TMD consists of six a-helices
spanning in and out of the membrane connected by coupling helices (CH) and
extracellular loops. TMD = transmembrane domain; NBD = nucleotide-binding
domain.
L.P. Tangella, M. Arooj, E. Deplazes et al. Computational and Structural Biotechnology Journal 19 (2021) 691–704
692
The X-ray crystal structure of mouse Pgp1 (apo form; PDB ID
4Q9H, with a resolution of 3.4 Å) was chosen as a template for
sequence alignment due to its relatively high structural resolution.
Sequence alignment of human ABCB5 and mouse Pgp1 was gener-
ated using Clustal Omega and visualised using BioEdit (V7.2.5)
[34]. All templates used in the modelling of the structure of ABCB5
were in the open-inward facing conformation, which has a high
affinity for substrate binding.
The stereochemical quality of all models generated was
assessed using Ramachandran plots (Rampage) [69,70], QMEAN
[5], ERRAT [11] and Verify-3D [16]. These programs estimate the
quality of the protein structural model upon analyses of the
torsional angles of amino acid residues, distance-dependent
all-atom interaction potentials, non-bonded interactions between
different atoms types, and provide a score by comparing these val-
ues with highly refined structures, or by comparing the 3D profile
of the protein with its own amino acid sequence [5,11,69]. The best
model was selected based on the above functions. The linker region
of the best ABCB5 model was refined using the loop optimisation
function in MODELLER [40].
2.3. Molecular dynamics simulations
2.3.1. Construction of lipid bilayer membrane systems
Model cell membrane systems consisting of two different
phospholipid compositions were constructed: POPC-cholesterol
(1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine and choles-
terol) and POPC-POPE-cholesterol (1-palmitoyl-2-oleoyl
-sn-glycero-3-phosphocholine, 1-palmitoyl-2-oleoyl-sn-glycero-
3-phospho- ethanolamine and cholesterol) using MemBuilder II
[30]. The POPC-cholesterol membrane was built as a symmetric
lipid bilayer, composed of 160 POPC and 20 cholesterol molecules
in an 80:20 wt% ratio (89:11 mol% ratio) in each leaflet. The POPC-
POPE-cholesterol membrane was modelled as an asymmetric lipid
bilayer composed of POPC, POPE and cholesterol in a 67:13:20 wt%
ratio (72:15:13 mol% ratio). The POPC-POPE-cholesterol mem-
brane consisted of 150 POPC and 30 cholesterol molecules in the
outer leaflet and 110 POPC, 54 POPE and 16 cholesterol molecules
in the inner leaflet. The POPC-cholesterol membrane system has
been reported to be more suitable for molecular simulations with
Pgp1 than the traditional DMPC-cholesterol (dimiristoylphoshati-
dylcholine) system [21,82] because unsaturated lipids better
mimic eukaryotic membranes. Since ABCB5 has been reported to
be predominantly expressed in pigmented cells [9], a POPC-
POPE-cholesterol membrane system was built to mimic the mela-
noma cell membrane [68]. The POPE levels in melanoma cells have
been reported to be relatively low and located predominantly in
the inner (cytoplasmic) leaflet [17]. Hence, all POPE molecules in
the POPC-POPE-cholesterol membrane system were placed in the
inner leaflet. Both membranes were solvated with 10,780 water
molecules. In each system, 94Na+ and 94Cl ions were added to
give a final ionic strength of 150 mM NaCl [62]. Each membrane
system was energy minimised, after which steric clashes from
water and lipid molecules were removed with two short, sequen-
tial NVT (1 ns) and NPT (1 ns) simulations. This was followed by
a production simulation of 400 ns. All simulation parameters were
set as outlined in the simulation parameters subsection. The area
per lipid (APL) and bilayer thickness were used to monitor the
equilibration of the membranes. The final frames in each simula-
tion trajectory were used to set up the protein-membrane systems,
as described below.
2.3.2. Assembly of protein-membrane systems
Histidine (His) residues 145, 581 and 1212 in the ABCB5 model
were protonated to give a positive charge to each as these residues
were reported to be crucial for the stability of the protein in a lipid
bilayer system [62]. Other His residues were modelled in their neu-
tral form. After energy minimisation using the steepest descents
algorithm, the protein was combined with each one of the
pre-equilibrated membranes to construct two protein-membrane
systems, ABCB5-POPC-cholesterol and ABCB5-POPC-POPE-
cholesterol. The OPM database [51] was used to predict the posi-
tion of the transmembrane helices (TMHs) in the lipid bilayer.
The ABCB5-POPC-cholesterol protein-membrane system was sol-
vated with 35,267 water molecules, and the g_membed tool in
GROMACS was used to remove overlapping lipids, which resulted
in a membrane composed of 155 POPC and 21 cholesterol mole-
cules in the outer leaflet and 156 POPC and 17 cholesterol mole-
cules in the inner leaflet. The net positive charge of the protein
(6+) was neutralised with 6 Cl ions and a further 157 Na+,
8 Mg+2 and 179 Cl ions were added to give a final physiological
ionic strength of 150 mM NaCl and a concentration of 5 mM MgCl2
to the ABCB5-POPC-cholesterol system.
Similarly, the ABCB5-POPC-POPE-cholesterol protein-
membrane system was solvated with 33,802 water molecules,
and overlapping lipids were removed as above, resulting in a mem-
brane composed of 144 POPC and 32 cholesterol molecules in the
outer leaflet and 107 POPC, 50 POPE and 13 cholesterol molecules
in the inner leaflet. The net positive charge of the protein (6 + ) was
neutralised with 6Cl ions and a further 154 Na+, 8 Mg+2 and 176
Cl ions were added to achieve the same ionic strength and
concentration of MgCl2 as the ABCB5-POPC-cholesterol system.
The systems were energy minimised using the steepest descents
algorithm, after which the system was relaxed with two short,
sequential NVT (1 ns) and NPT (1 ns) molecular dynamics (MD)
simulations. Each system was then simulated under NPT condi-
tions for at least 200 ns. Equilibration of the protein was monitored
by measuring the root-mean-square deviation (RMSD) of the back-
bone atoms in the whole protein, the NBD and TMHs, using the
starting structure as the reference. Standard deviations of RMSD
values and two-sided confidence intervals (CI) were used to assess
whether differences in RMSD between different protein domains
were statistically significant. For each protein-membrane system,
the dominant conformations of the protein were identified by
RMSD clustering analysis using the trajectory frames from the final
50 ns of the corresponding simulation, using all atoms in the TM
domains with a RMSD cut-off of 0.15 nm, as described previously
[13]. Root-mean-square fluctuations (RMSF) for each amino acid
residue were computed using the last 50 ns of each simulation in
order to assess whether the different membrane environments
change the mobility of the various protein domains.
2.3.3. MD simulation parameters
Gromacs 4.6.7 [86] was used for all MD simulations with the
Slipids force field [41] for lipids and the Amber99SB force field
[50] for protein and ions. Water molecules were represented using
the TIP3P water model [43]. Initial velocities were randomly
assigned from Maxwellian distributions. Periodic boundary condi-
tions were applied throughout all simulations. All NVT (isochoric-
isothermal) ensemble simulations used the velocity-rescale ther-
mostat [8]. All other simulations were carried out in the NPT
(isobaric-isothermal) ensemble at 1 atm pressure and 298 K using
the Nosé-Hoover [37,61] thermostat and the Parrinello–Rahman
barostat [66] using a semi-isotropic pressure coupling scheme
and the isothermal compressibility of water (4.5  105 bar1).
Long-range electrostatic interactions were treated using the
Particle-Mesh Ewald (PME) scheme [12] with a real-space cut-off
of 1.4 nm and a Fourier spacing grid of 0.12 nm. Van der Waals
interactions were described using a Lennard-Jones potential with
a cut-off of 1.4 nm. Long-range dispersion corrections were applied
to the pressure and potential energy. The LINCS algorithm [36] was
used to constrain all covalent bonds. A time step of 2 fs and 1 fs
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was used for the membrane simulations and the protein-
membrane simulations, respectively.
2.4. Molecular docking simulations
Molecular docking simulations were performed using the dom-
inant conformation of ABCB5 calculated using the final 50 ns of the
production runs of the ABCB5-POPC-POPE-cholesterol protein-
membrane system. This dominant conformation was identified
using clustering analysis on 500 structures from the last 50 ns of
the corresponding simulation, using all atoms in the TM domains
with a RMSD cut-off of 0.15 nm, as described previously [13].
The ligand structures for rhodamine 123, doxorubicin, daunoru-
bicin, paclitaxel, docetaxel, mitoxantrone, etoposide, camp-
tothecin, vincristine and 5-flourouracil (5-FU) were downloaded
from the ZINC15 database [81] (Fig. S5 in the Supplementary Infor-
mation), energy-minimised using the steepest descents algorithm
in Avogadro v.1.2.0 [35] using the MMFF9s force field, and
exported as PDB files. PDBQT files with appropriate atomic charges
were generated for all ligands using AutoDock Tools V.1.5.6 [60],
which were then used for molecular docking simulations. The
default protonation states at physiological pH may be incorrect
for some ligands, such as doxorubicin and rhodamine-123. There
is evidence that a different protonation state may be prevalent at
physiological pH for these compounds [25]. As the relevant proto-
nated groups in those molecules already form H-bonds, addition of
the charge would only strengthen that interaction. As the binding
site location within the TMD region is unknown, the grid box was
set for the entire transmembrane domain. A 40  40  40 Å3 grid,
centred at the centroid of the internal cavity with a grid spacing of
1.0 Å was used. The exhaustiveness parameter was manually set to
50 due to the large search space volume required, consistent with a
prior docking simulation study of Pgp1 [22,19]. Docking simula-
tions were performed using AutoDock Vina v1.1.2 [84]. For each
compound, the ligand–protein contacts were evaluated through
the analysis of all top-ranked docking modes using BIOVIA Discov-
ery Studio Visualiser V2.5.5 (Dassault Systèmes) and PyMOL [77].
The number of residues and the nature of interactions (non-
bonded and hydrogen bonds) were assessed.
3. Results and discussion
3.1. Model of full-length ABCB5 transporter
As expected, all models comprised of two TMDs and two NBDs
with an open-inward facing conformation (Fig. 2a). The two halves
of the transporter, TMD1-NBD1 of the N-terminus (coloured in yel-
low) and TMD2-NBD2 of the C-terminus (coloured in blue) are
interconnected by a linker region (coloured in green) (Fig. 2a).
The secondary structure content of the ABCB5 models includes
eight b-sheets in the NBDs, and twelve a-helices (six in each
TMD), similar to the topology predictions reported previously
using HMMTOP [59]. The core of each NBD consists of four parallel
and four anti-parallel b-sheets (Fig. 2a, close up view in the box),
comprising the ABC signature (LSGGQ; highlighted in black),
Walker A (GSSGCGKS; highlighted in blue) and Walker B (high-
lighted in purple) motifs. The ABC signature motif is a small, a-
helical fragment of 5 amino acids. The Walker A motifs in the
ABCB5 model exhibited a coiled loop and a short a-helix (P-loop)
rich in glycine, while the Walker B motifs (ILLLD) have a b-sheet
conformation. These three motifs were conserved between Pgp1
and ABCB5 in NBD2 but showed slight variation in NBD1 of ABCB5,
where the Walker A motif sequence (GLNGSGKS) varies by two
amino acids (Leu422 and Asn423). The ABC signature and Walker
B motif sequences in NBD1 of ABCB5 are found to be MSGGQ and
ILLID, respectively (Fig. S1), and vary by one amino acid, namely
Met525 and Ile555, respectively. Cross-linking of the ABC
signature motif and Walker A motif site is essential for coupling
drug binding with ATP hydrolysis [52]. The impact of these
sequence variations in these crucial motifs on the transport cycle
of ABCB5 is unknown.
The TMDs consists of twelve a-helices that span in and out of
the membrane whilst remaining interconnected by coupling
helices (CH) or extracellular loops (ECL). Each TMD1 consists of
six TMHs, 1–6 (shown in yellow), whilst TMD2 is made of TMHs
7–12 (shown in blue) (Fig. 2a). A central cavity containing the
putative drug binding sites is enclosed within the twelve TMHs.
Two portal gates that allow the entry of the drug from the cell
membrane are present in the ABCB5 model, with similar architec-
ture as in Pgp1 [49]. Portal gate 1 is formed by TMHs 4 and 6,
whilst portal gate 2 is formed by TMHs 10 and 12 and is only par-
tially open (Fig. 2b).
The linker region that connects the two halves of the ABC trans-
porter was previously reported to play an important role in the
function and stability of human Pgp1 transporters [22,24,38,76].
The models generated by PHYRE2 and MODELLER either have a
missing linker or lack an intact linker. All templates used for mod-
elling of ABCB5 (including PDB structures 3G5U, 3G60, 4F4C and
4Q9H) lack an intact linker. The missing linker region in the tem-
plate was predicted by SWISS MODEL and I-TASSER to have a ran-
dom coil conformation by ab initio modelling. Deletion of the 34
residues from the linker region of human Pgp1 did not change
the membrane trafficking of the protein but led to the loss of cat-
alytic activity [76]. Shortening of linker region in murine Pgp1 by
deleting the 34 residues corresponding to the 34 residues removed
in human Pgp1 showed loss of ATPase activity due to the binding of
molecules only at NBD1 [18]. Therefore, the linker region is consid-
ered to have a prominent role in the transporter activity than just
connecting the two halves [24].
The stereochemical quality of all models was estimated by
Ramachandran plots, QMEAN, ERRAT and Verify 3D. All models
had an acceptable global quality score, except models generated
by Phyre2 intensive mode and I-TASSER. For models generated
by Phyre2 intensive mode and I-TASSER, the percentage of residues
in the favourable regions of the Ramachandran plot was <90%
(Fig. S1 in the Supplementary Information). The relatively low
quality of the models generated by Phyre2 and I-TASSER can be
attributed to the template chosen for modelling (PDB ID 3G5U,
with a resolution of 3.8 Å). This template corresponds to the crystal
structure of mouse Pgp1 previously reported to have structural dis-
tortions in the transmembrane helices (TMHs) [49]. A revised crys-
tal structure of mouse Pgp1 (PDB ID 4MIM, with a resolution of
3.8 Å) was later deposited with significant corrections in TMHs
3–5, 8, 9 and 12, coupling helices and intracellular helices (IH)
IH1, IH3 and IH4, both elbow helices, both TMD-NBD connectors
and minor corrections to all extracellular loops [49]. As the tem-
plate selection in Phyre2 was automated [45], this was unavoid-
able. Based on this, five additional models were generated using
I-TASSER after ensuring the inclusion of this revised structure
(PDB ID 4M1M) and excluding distorted structures (PDB structures
3G5U, 3G60 and 3G61) from template selection for threading.
However, this did not noticeably improve the quality of the pre-
dicted models (Fig. S1, models 18–22), suggesting that the low
quality of these models was not wholly the result of the choice
of template. Overall, the model generated by SWISS-MODEL based
on the crystal structure of mouse Pgp1 (PDB ID 4Q9H, with a res-
olution of 3.4 Å) was found to have the highest global score. Hence,
this model was chosen for further studies and is hereafter referred
to as the ABCB5 model. Loop refinement of the linker region of the
ABCB5 model was performed using the loop optimisation function
in MODELLER [40].
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Upon superimposition of the entire structure of the template
(PDB ID 4Q9H) with the ABCB5 model, the TMDs and NBDs aligned
with minimal deviations (Fig. S2 in the Supplementary Informa-
tion). Larger deviations were observed in the extracellular loops
and intracellular coils. Large structural changes are known to occur
in ABC transporters when transitioning from the resting to active
state and vice versa, as evidenced by crystal structures and molec-
ular simulation studies [2,20,31,39,47,87]. This could result in high
plasticity in the putative binding sites of the ABCB5 transporter,
affecting the accessibility of the amino acids residues that may
potentially interact with the ligand and thereby, making it chal-
lenging to predict the location of binding sites by molecular dock-
ing. Hence, MD simulations of the ABCB5model in the resting-state
conformation were conducted to characterise its conformational
stability in a model cell membrane environment, as well as to
determine if a single structure or an ensemble of conformations
is required for subsequent molecular docking simulations aimed
at predicting the putative binding sites in the transporter.
3.2. Conformational dynamics of the resting-state conformation of
full-length ABCB5 in a model cell membrane
The conformational behaviour of the ABCB5 model in a
model cell membrane environment was investigated using unre-
strained MD simulations. Several studies have reported the
influence of the lipid bilayer and the linker region on the con-
formation of ABC transporters [3,14,21,39,62,65]. These studies
revealed structural deformations when mouse Pgp1 was placed
in a POPC-cholesterol membrane in the presence of 150 mM
NaCl. However, the structure was found to be stabilised by
the addition of Mg+2, which match physiological conditions
and the protonation of the catalytic His residues [62]. Therefore,
these same conditions were used in our MD simulations. The
protein was simulated in two different model cell membranes
to characterise the influence of lipid composition and leaflet
lipid content asymmetry on the structural dynamics of ABCB5
in its resting conformation and the conformation of the putative
drug binding sites.
The lipid composition of the first membrane was POPC-
cholesterol in a 89:11 mol % ratio, which is similar to several pre-
vious simulations of Pgp1 [21,39,62]. The lipid composition of the
second membrane was POPC-POPE-cholesterol in a 72:15:13 mol %
ratio, which is based on the lipid composition of melanoma cells
[68]. This approach is supported by a recent study that investigated
the impact of different membrane systems (POPE, DOPE, DPPE,
POPC, DOPC and DPPC bilayers) on Sav1866, a bacterial ABC trans-
porter, and which revealed that the conformational dynamics of
Sav1866 was lipid-dependent, with large-scale conformational
Fig. 2. Structure of the human full-length ABCB5model. (a) Representative ABCB5model generated by SWISS-MODEL. The TMD1 and NBD1 are coloured in yellow, TMD2 and
NBD2 are coloured in blue. The linker region is coloured in green. The a-helices are shown as cartoons. A close-up view of NBD1 in the box shows the secondary structure of
NBD1, comprising of a-helices (golden yellow), b-strands and sheets (red) interconnected by coils (green). The Walker A, Walker B and ABC signature motifs are coloured in
blue, purple and black, respectively. (b) Portal gates 1 and 2 in the ABCB5 model. The model (shown with a pale blue surface view) consists of two potential portal gates:
portal gate 1 formed by TMHs 4 and 6 (left), and portal gate 2 formed by TMHs 10 and 12 (right). (For interpretation of the references to colour in this figure legend, the reader
is referred to the web version of this article.)
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changes observed in POPE bilayers and, to a lesser extent, in DOPE
and DPPE bilayers [39].
The PPM server was used to predict the relative position and
rotation of the twelve TMHs of ABCB5 in the membrane systems
(Table S2 in the Supplementary Information). As expected, the
resulting protein arrangement in the membranes revealed that
the N-terminus of the ABCB5 model has an intracellular or cytoso-
lic location, as in Pgp1 [42,49,83].
The backbone root-mean-square deviation (RMSD) of the entire
protein, NBDs and TMHs were used as a measure of the average
deviation with respect to the initial structure of the ABCB5 model
to assess the stability of the transporter (Fig. 3a). A stable confor-
mation was reached after ~100 ns in the POPC-cholesterol mem-
brane system and after ~50 ns in the POPC-POPE-cholesterol
membrane system. Root-mean square fluctuations (RMSF)
(Fig. S4) show that there is no difference in the conformational
flexibility of the different protein domains in the two membrane
environments. The RMSD data further shows that in both mem-
brane systems, the TMHs appeared to be the more stable domain,
with lower structural deviations compared to the NBDs. The RMSD
of the NBDs was found to be significantly higher (confidence level
99%) than that of TMHs. Superimposition of the initial structure of
the ABCB5 model (shown in grey in Fig. 3b) with the structures
obtained at the end of 200 ns of simulation in POPC-cholesterol
(left) and POPC-POPE-cholesterol (right) shows a small shift in
the entire TMHs towards the internal cavity occurred in both mem-
brane systems, which decreases the volume of the internal cavity.
The NBDs also shifted towards each other, decreasing the volume
of the ATP binding cavity (see also Movies 1 and 2 in the Supple-
mentary Information). Previous studies also reported a decrease
in the volume of the central cavity of Pgp1 (PDB ID 3G5U), with
more water molecules being replaced from the centre of the TM
pore in the simulated conformation [20,62]. In particular, the
motion of the NBDs to form a more closed internal cavity was
observed in simulations of Pgp1 in a membrane environment [62].
Based on the time evolution of the RMSD of the protein, we con-
sidered the first 150 ns of the simulation as equilibration and only
the last 50 ns were used for subsequent analysis. For both protein-
membrane systems, 500 frames from these last 50 ns were used for
clustering analysis of the putative rhodamine 123 binding residues
in human full-length ABCB5. The rhodamine 123 binding amino
acid residues in human Pgp1, identified by previous site-directed
mutagenesis studies [15,53–55], were mapped onto the human
ABCB5 sequence (Table S3 in the Supplementary Information)
and used for clustering analysis. The mapped residues in human
ABCB5 include Phe330, Tyr337, Phe709, Tyr750, Tyr933, Tyr963,
Met966, Ala967 and Glu970. RMSD clustering was conducted for
the main chain of the TMDs containing these nine putative rho-
damine 123 binding residues with a RMSD cut-off of 0.15 nm,
which resulted in a single cluster. This indicates that there is lim-
Fig. 3. Conformational behaviour of ABCB5 during the molecular dynamics simulations. (a) Evolution of the RMSD of the entire protein, transmembrane helices (TMHs) and
nucleotide-binding domains (NBDs) in the POPC–cholesterol membrane (left), and the POPC–POPE-cholesterol membrane (right). (b) The final conformations of ABCB5 at the
end of the simulations in the POPC-cholesterol (left, pale pink) and POPC-POPE-cholesterol (right, orange) membrane systems are overlayed on to the initial ABCB5 model
(shown in grey). (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
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ited motion of the main chain of the putative binding region during
the simulations. Fig. 4 shows the superimposition of the rho-
damine binding residues in the ABCB5 model with their corre-
sponding conformations during the final 50 ns of simulation in
the POPC-POPE-cholesterol model. Relatively minor shifts were
observed in the orientation of the sidechains of most residues,
except Phe709, Tyr963 and Glu970. Based on this finding, we used
a central structure of the single cluster as the conformation for
docking simulations.
Comparison of the Ramachandran plots of the initial ABCB5
model and its structure after 200 ns of simulation in the POPC-
cholesterol and POPC-POPE-cholesterol membrane environments
revealed a slight reduction in the percentage of residues in outlier
(unfavoured) regions from 1.2% to 0.6 and 0.7%, respectively
(Table 1). Some residues in the outliner regions in the structures
at the end of the simulations were now found in the favourable
or allowed regions of the Ramachandran plot. This could be due
to the structural reorganisation of the NBDs and may be behind
the observed increase in RMSD (Fig. 3). The remaining outlier resi-
dues corresponded largely to the linker region (Fig. S3 in the Sup-
plementary Information), except for Leu1036, Ser1051 and
Arg1244 of the NBD2 region. The quality of the ABCB5 models in
the two membrane environments was very similar as judged by
the Ramachandran plots, QMEAN scores and ERRAT plots. How-
ever, the VERIFY-3D score was slightly higher for ABCB5 in the
POPE-POPC-cholesterol system. A slightly distorted and inward
pivot (towards the internal cavity) was observed in the NBD2 of
the ABCB5 model at the end of the simulation in the POPC-
cholesterol membrane. Previous MD simulations of mouse Pgp1
in a POPC-cholesterol membrane also reported inward pivots in
the NBD regions [21,58,62]. Interestingly, no such pivots were
observed in the NBDs in the structure of ABCB5 at the end of the
simulation in the POPC-POPE-cholesterol membrane. Small
changes in the NBDs are known to correspond to large deviations
in the TMHs and vice versa [52]. Consequently, the ABCB5-POPC-
cholesterol membrane system was not considered any further for
the molecular docking studies.
3.3. Putative drug binding sites of full-length human ABCB5 identified
by molecular docking
The entire internal drug-binding pocket of the ABCB5 model
was used as the docking simulation cell. Three putative binding
sites, sites 1, 2 and 3, were identified in full-length human ABCB5
from the top-ranked docking modes of ten chemotherapeutic
drugs, previously identified as substrates of the human full-
length ABCB5 transporter (Fig. 5a). The location of these three
putative binding sites in human ABCB5 overlapped with the loca-
tion of three binding pockets in human Pgp1 referred to as the
prazosin-, H- and R-sites, respectively [2,22,19,49,57,78]. Further-
more, we used site-directed mutagenesis data for rhodamine 123
and the structure of the complex of paclitaxel with human-
mouse chimeric Pgp1 (PDB structure 6QEX) as a reference for our
molecular docking predictions. Both rhodamine 123 (a fluorescent
dye) and paclitaxel (a chemotherapeutic drug) are common sub-
strates of human Pgp1 and ABCB5 [44,46,57,85].
All nine, top-ranked binding modes of rhodamine 123 in human
ABCB5 were predicted to be located in a cavity closer to the outer
leaflet (Fig. 5b) with a free energy of binding (DGb) ranging from
8.4 to 7.2 kcal/mol. This suggests that binding of rhodamine
123 in ABCB5 could be restricted to a single binding pocket, as is
the case in Pgp1. A total of 17 residues outlining this cavity in
human ABCB5 were identified, and the binding site is hereafter
referred to as site-1 (Table S3). Site-1 in human ABCB5 involved
TMHs 1, 5, 6, 7 and 12, which is consistent with the site-directed
mutagenesis data for the rhodamine 123 binding site in human
Pgp1 (TMHs 1, 6, 7, 9 and 12) [57,74]. An overlay of the rhodamine
123 binding site residues in human Pgp1 and human ABCB5 is
shown in Fig. 5c and 5d. Next, we compared these 17 putative
interacting residues in human ABCB5 with the 9 residues in human
Pgp1 identified by biochemical studies (Table S3). Six (four con-
served and two semi-conserved) out of the 17 residues matched
the site-directed mutagenesis data in Pgp1, namely Phe330,
Phe709, Tyr933, Tyr963, Met966 and Glu970, confirming the high
structural and sequence similarity in the binding site between the
two proteins. The conserved residues in ABCB5, Phe330, Phe709,
Tyr933 and Met966, mainly formed hydrophobic interactions or
hydrogen bonds with rhodamine 123, whilst the semi-conserved
residues Tyr963 and Glu970 formed hydrogen bonds. The residues
that were not identified by molecular docking include Tyr337,
Tyr750 (semi-conserved) and Ala967 (conserved) (Table S3). The
steric clashes in the model and the possible variation in the orien-
tation of the sidechains of the neighbouring residues of these three
residues could potentially have hindered potential interactions
with the ligand. Seven additional residues were identified by
Fig. 4. The registered shift in the sidechain atoms of the putative rhodamine 123
binding residues in the ABCB5 model simulated in a POPC-POPE-cholesterol bilayer.
Overlay of the sidechain atoms (shown as sticks; coloured in aqua blue) of the
mapped putative rhodamine 123 binding sites in the ABCB5-POPC-POPE-choles-
terol system in the final 50 ns. The protein structure is shown in cartoon
representation. (For interpretation of the references to colour in this figure legend,
the reader is referred to the web version of this article.)
Table 1
Quality of the ABCB5 model before and at the end of the MD simulations.
System Residues in Ramachandran plot (%) QMEAN ERRAT VERIFY-3D (%)
Favoured Allowed Unfavoured
ABCB5 model 94.4 4.4 1.2 2.96 95.70 48.05
ABCB5-POPC-cholesterol 94.4 5.0 0.6 4.29 96.69 53.91
ABCB5-POPC-POPE-cholesterol 93.9 5.5 0.7 4.15 96.26 56.60
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molecular docking as potential interacting residues in human
ABCB5: Met65, Tyr295, Met298, Tyr302, Ile333, His334 and
His706. Of these seven residues, Met65 and Tyr302 are conserved
whilst Tyr295 are semi-conserved. These seven residues formed
weak hydrogen bonds and hydrophobic interactions with rho-
damine 123. Two (Met65 and Tyr302) out of seven residues are
conserved, while five are non-conserved between Pgp1 and ABCB5.
The steric clashes in the model and the possible variation in the
orientation of the sidechains of neighbouring residues of these
seven residues could potentially lead to these other interactions.
However, the prediction of false positive interactions by AutoDock
Vina is, of course, possible. Thus, despite finding good agreement in
the interactions with the residues mapped from site-directed
mutagenesis of human Pgp1, further experimental studies are
required to validate these predictions.
Previous molecular docking simulations of rhodamine 123 with
mouse Pgp1 (PDB ID 3G5U) using AutoDock Vina showed that rho-
damine 123 binds to the R-site and prazosin-site with equal affin-
ity (DGb = 9.2 kcal/mol) [22,19]. However, in our docking
simulations, rhodamine 123 was predicted to only interact with
the prazosin-site (i.e. site-1; DGb = 8.4 kcal/mol). This could be
due to differences in the identity of interacting residues and the
Fig. 5. Putative binding sites in the ABCB5 model predicted by molecular docking. (a) Location of the three putative binding sites: site-1 (blue), site-2 (red) and site-3 (green)
in human ABCB5 model (shown in grey cartoon). (b) Top-ranked docking pose for rhodamine 123 (shown in cyan with hetero atoms such as oxygen and nitrogen coloured in
red and blue, respectively) in site-1 of the ABCB5 model (shown in golden yellow in cartoon representation). (c) Ligand-protein interactions of rhodamine 123 in human
ABCB5. Rhodamine 123 is shown as sticks and coloured cyan (hetero atoms such as oxygen and nitrogen are coloured in red and blue, respectively. Hydrogen atoms are not
shown). The interaction residues in ABCB5 are shown in golden yellow, and Pgp1 is shown in grey and (d) Two-dimensional representation of the ligand–protein interaction
of the top-docked pose of rhodamine 123. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
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conformation of sidechains between human ABCB5 and mouse
Pgp1. Moreover, the DGb values of rhodamine 123 in human
ABCB5 was less negative than that reported with Pgp1, suggesting
a lower affinity of rhodamine 123 for ABCB5. We used the recently
reported crystal structure of human-mouse chimeric Pgp1 co-
crystallised with paclitaxel to validate our docking predictions of
paclitaxel in human ABCB5 [1]. Our docking simulations predicted
that paclitaxel interacts with two binding pockets in ABCB5,
namely site-1 (DGb = 9.3 kcal/mol) and site-2 (8.2 kcal/mol)
(Fig. 5d). In Pgp1, paclitaxel was found to bind to the prazosin-
site (i.e. site-1), in line with our findings (Fig. 6a) because the lower
DGb value predicted for site-1 indicates preferential binding to
site-1 over site-2. The interacting residues in ABCB5 were identi-
fied and are listed alongside those of Pgp1 in Table S4 in the Sup-
plementary Information. The putative interacting residues in
ABCB5 identified by molecular docking (28 residues) were com-
pared with the residues in the crystal structure of human-mouse
chimeric Pgp1. Nine out of the 28 interacting residues predicted
by the docking simulations match the residues found to interact
with paclitaxel in the crystal structure (Fig. 6, Table S4). Five of
these nine residues are conserved and showed hydrophobic inter-
actions and hydrogen bonds with paclitaxel. The non-matching
residues are not conserved between the two structures and mostly
formed hydrogen bonds, with a few hydrophobic interactions. Nev-
ertheless, the binding region for paclitaxel predicted in human
ABCB5 (site-1) is in good agreement with the binding sites in
human Pgp1, determined by biochemical and X-ray diffraction
crystallography data. Finally, a validation docking simulation of
paclitaxel with the human-mouse chimeric structure of Pgp1
(PDB ID 6QEX) using similar parameters resulted in nine binding
poses of this ligand within the prazosin binding site, all with very
similar interactions to those observed in the crystal structure
(Fig. S6).
The binding sites in human ABCB5 for nine other chemothera-
peutic drugs considered in this study were predicted (Table S5).
Anthracyclines (doxorubicin and daunorubicin) were predicted to
bind to two sites, site-1 and site-2 (Fig. 7a). In Pgp1, doxorubicin
had been reported to bind to the R-site and prazosin-site by previ-
ous biochemical and in silico studies [22,19,79], in agreement with
our predictions. Three top-ranked binding poses of doxorubicin
were predicted at site 2 (DGb = 8.3 to 7.9 kcal/mol), and six at
site-1 (DGb = 7.7 to 7.4 kcal/mol). The DGb values of daunoru-
bicin (10.3 to 9.3 kcal/mol) were lower than doxorubicin (-8.3
to 7.4 kcal/mol), and seven binding poses were found at site-1
(DGb = 10.3 to 9.0 kcal/mol) and two at site-2 (9.3 kcal/mol).
In the case of docetaxel, all nine predicted binding poses were
found at site-1 (DGb = 9.1 kcal/mol). The DGb values of taxanes
(paclitaxel and docetaxel) at site-1 were lower than those of
anthracyclines, indicating a higher affinity of taxanes for site-1.
All nine predicted binding poses for docetaxel were found at site-
1 (Fig. 7a), whereas paclitaxel was predicted to interact at both
site-1 and site-2. Vincristine was also predicted to bind to site-1
and site-2, similar to the anthracyclines. The DGb value of vin-
cristine was 8.5 at site-1 and 8.0 kcal/mol at site-2. Overall,
the predicted binding poses of anthracyclines and taxanes revealed
two putative binding sites, site-1 and site-2, identified for the first
time in our study [44].
Docking simulations of etoposide and camptothecin predicted
that these drugs bind to site-1 and site-2, whilst mitoxantrone
and 5-FU were predicted to bind to a cavity closer to the inner leaf-
let towards the N-terminus, hereafter referred to as site-3 (Fig. 7b).
The DGb values at site-1 and site-2 for the top-ranked poses of
camptothecin (9.3 to 8.6 kcal/mol) and etoposide (9.6 to
8.9 kcal/mol) were similar. Mitoxantrone was predicted to bind
to site-1 as well as site-3, with equal DGb (7.7 kcal/mol). The
location of site-3 overlaps with the H-site in human Pgp1. The
Fig. 6. Putative paclitaxel binding site in the ABCB5 model. (a) Location of the putative paclitaxel binding pocket in human ABCB5 model. The top ranked docked pose of
paclitaxel (cyan sticks) is superimposed with the binding mode of paclitaxel observed in the X-ray structure (pink sticks). The ABCB5 model is shown in golden yellow. (b and
c) Side chains interacting with paclitaxel in the human ABCB5 model and human-mouse chimeric Pgp1 residues, parallel to the membrane plane. The interacting sidechains in
human ABCB5 and human-mouse chimeric Pgp1 are shown in golden yellow and green, respectively. The heteroatoms in the ligands and the residues such as oxygen,
nitrogen and sulphur is shown in red, blue and orange, respectively. Hydrogens are not shown. (For interpretation of the references to colour in this figure legend, the reader is
referred to the web version of this article.)
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two binding sites, H- and R-sites in Pgp1, have been reported to act
cooperatively with each other [78]. In human ABCB5, the existence
of such cooperativeness between site-2 and site-3 is unknown and
requires thorough investigation.
Docking simulations of 5-FU predicted that it binds to all three
binding sites but with different affinities. Nevertheless, the DGb of
5-FU was substantially lower (5.8 to 4.8 kcal/mol) than for all
other molecules considered in this study. Previous in vitro studies
revealed that 5-FU does not act as a substrate for human full-
length ABCB5 transporter in HEK293 cells overexpressing the
ABCB5 transporter [44], in line with our predictions. Contrary to
this finding, however, a positive enrichment of ABCB5-expressing
cells in colorectal cancer following neoadjuvant treatment with
5-FU indicated that 5-FU is a substrate of ABCB5 [89]. It is unclear
whether these contrasting observations for 5-FU could be attribu-
ted to the ABCB5b isoform and whether the two isoforms have dif-
ferent substrate specificity. Nonetheless, the docking simulations
of the full-length ABCB5 predict that 5-FU has low affinity, which
suggests that 5-FU might exhibit weaker interactions with ABCB5.
3.4. Characterisation of the putative drug binding sites
Following the identification of the three binding sites in the
internal cavity of ABCB5, the characterisation of these binding sites
was carried out. The amino acid residues lining the three putative
binding sites were identified and listed in Table 2 as well as
Table S6 (provided as a .xlsx file) in the Supplementary Informa-
tion. Only two out of the ten chemotherapeutic drugs considered
Fig. 7. Putative binding sites in full-length human ABCB5 for the chemotherapeutic drugs (a) doxorubicin, daunorubicin, docetaxel and vincristine; (b) Etoposide,
camptothecin, mitoxantrone and 5-FU. The image represents the top docking mode of each ligand in each drug binding site (if present). The docking pose of each of these
ligands is represented as sticks.
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were found to bind to site-3, so more drugs that bind to this site
need to be identified to better characterise the site. The amino
acids found in the three sites are plotted as a bar graph (Fig. 8a).
The percentages of hydrophobic residues (Ala, Val, Leu, Ile, Phe,
Cys and Met) in site-1, site-2 and site-3 were found to be 45, 40
and 33%, respectively (Fig. 8b), possibly attributed not only to the
transmembrane location of these drug binding sites but also to
the hydrophobic nature of the drugs that bind to ABCB5. The
drug-binding sites in Pgp1 have also been reported to be
hydrophobic, and most ligand–protein interactions in Pgp1 involve
hydrophobic interactions [80]. Table S7 in the Supplementary
Information lists all of the amino acid residues in sites 1–3 of
human ABCB5 and the corresponding residues in mouse Pgp1
(PDB ID 4Q9H). Only a small proportion of residues are conserved
between ABCB5 and Pgp1, with the majority being semi and non-
conserved residues, which are thought to contribute to the sub-
strate specificity of ABCB5.
The putative site-1 in human ABCB5 is composed of ~20% aro-
matic residues (namely Phe and Tyr), whilst site-2 is composed
of only 4% aromatic residues. No aromatic residues were found in
site-3. Site-2 was found to have relatively more aliphatic non-
polar residues. The percentage of aliphatic non-polar residues
(Gly, Ala, Val, Leu, Ile and Pro) in site-1, site-2 and site-3 were
39, 50 and 29%, respectively. The percentage of polar residues
(Ser, Thr, Cys, Met, Asn and Gln) in site-1, site-2 and site-3 were
34, 22 and 29%. Negatively charged amino acids (Asp and Glu)
are more abundant in site-3 (24%) compared to site-1 (2%) and
site-2 (8%). Positively charged amino acids (Lys, Arg and His) are
more abundant in site-2 (18%) and site-3 (20%), compared to
site-1 (6%). Overall, site-1 and site-2 are mostly composed of aro-
matic, aliphatic, non-polar and positively charged residues, whilst
site-3 is mostly composed of polar and negatively charged
residues.
4. Conclusions
Full-length human ABCB5 has been reported to mediate
chemoresistance by drug effluxion, but its drug binding sites have
remained unknown. In this study, an atomistic model of the full-
length transporter was constructed with the highest quality using
the crystal structure of mouse ABCB1 as a template. The structural
model of ABCB5 comprises two TMDs and two NBDs intercon-
nected by a linker region. Molecular dynamics simulation of the
model was conducted in two membrane systems, namely POPC-
Table 2
Amino acid residues composing the three putative binding sites in ABCB5 identified by molecular docking simulations.
Site-1 Site-2 Site-3
Leu 62 Ser 710 Ser 225 Glu 762 Ile 125
Met 65 Phe 713 Arg 226 Ile 763 Ile 129
Pro 66 Leu 742 Val 228 Thr 765 Ala 132
Leu 69 Cys 746 Ile 229 Met 766 Ala 133
Leu 184 Tyr 750 Leu 231 Arg 769 Thr 136
Gln 187 Gly 810 Thr 232 Ile 800 Arg 140
Asn 188 Gln 818 Glu 235 Asp 801 Asp 172
Met 218 Asn 819 Leu 273 Ala 803 Ser 175
Ala 221 Asn 822 Ala 276 Gln 804 Asp 176
Ala 222 Leu 848 Lys 277 Gln 806 Asp 180
Leu 291 Thr 851 Gly 280 Gly 807 His 345
Tyr 295 Gly 852 Arg 283 Ala 808 Ile 854
Met 298 Met 853 Ser 287 Thr 809 Glu 855
Asn 299 Tyr 922 Lys 288 Ser 811 Thr 856
Tyr 302 Ser 925 Leu 678 Arg 812 Met 859
Ile 333 His 926 Leu 679 Ile 813 Asp 866
His 334 Ile 929 Leu 682 Gly 814 Lys 867
Tyr 337 Tyr 933 Lys 686 Val 815 Gln 907
Cys 338 Phe 955 Val 692 Leu 816 Thr 911
Gly 340 Thr 959 Gln 753 Val 973 Lys 914
Ala 341 Tyr 963 Gly 754 Leu 974 Ile 918
Asn 702 Met 966 Tyr 757 Ala 975
Val 705 Ala 967 Gly 758 Glu 977
His 706 Gly 969 Arg 759 Tyr 978
Pro 707 Glu 970 Gly 761 Lys 980
Phe 709
Fig. 8. Characterisation of the three putative drug binding sites in human ABCB5 predicted by molecular docking. (a) Amino acid residue distribution (in percentage) in the
three putative drug binding sites in full-length human ABCB5, (b) Percentage of hydrophobic residues in each of the three putative binding sites.
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cholesterol and POPC-POPE-cholesterol (to mimic melanoma cell
membranes) under similar physiological-like conditions. Larger
deviations in the loop regions and NBDs with minimal deviations
in the TMDs were observed in both membrane systems. The NBDs
of the model in the POPC-POPE-cholesterol membrane were stable,
whilst the NBDs of the model in the POPC-cholesterol membrane
pivoted towards the central cavity. The final configuration of the
ABCB5 model in the POPC-POPE-cholesterol membrane system
was then used for subsequent molecular docking simulations.
For the first time, three putative drug binding sites with distinct
properties in human full-length ABCB5 transporter were predicted
by molecular docking simulations. The putative binding sites of
rhodamine 123, paclitaxel, doxorubicin and daunorubicin are in
agreement with the biochemical and structural data available for
these compounds in human Pgp1. All compounds tested in this
study were predicted to interact with site-1 (the equivalent of
the prazosin-site in Pgp1) of the human full-length ABCB5 trans-
porter. This suggests that site-1 is possibly more accessible than
the other two binding sites. The predicted interactions made by
various drugs with these putative binding sites should be validated
by future biochemical studies of human ABCB5.
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